Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Resyca

## Sitemaps

- [XML Sitemap](https://resyca.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [News](https://resyca.com/resyca-news/)
- [Resyca Announces the Appointment of Deborah Jones as New CEO](https://resyca.com/resyca-announces-the-appointment-of-deborah-jones-as-new-ceo/) - Enschede, Netherlands, April 2, 2026 – Resyca®, a leader in soft mist-based drug delivery with its next-generation Soft Mist Inhalers and Soft Nasal Sprays, today announces the appointment of Deborah Jones, Ph.D., as Chief Executive Officer, effective immediately. She succeeds Remko Beimers, who is stepping down. The shareholders thank Mr Beimers for his leadership and
- [Evaluation of Rayleigh jet atomiser for intranasal delivery of lipid nanoparticle – siRNA formulations: stability, deposition, and device performance](https://resyca.com/evaluation-of-rayleigh-jet-atomizer-for-intranasal-delivery-of-lipid-nanoparticle-sirna-formulations-stability-deposition-and-device-performance/) - Authors: Haiqiao Wang, Yuan Zhang, Ye Zhang, Anthony Kelleher, Chantelle Ahlenstiel, Madeline X. Zhang, Cees J.M. van Rijn, Hui Xin Ong and Daniela Traini Journal: International Journal of Pharmaceutics, Volume 683, 2025 Abstract: The COVID-19 pandemic has emphasised the need for innovative and efficient drug delivery systems, particularly for nucleic acid-based therapeutics. Lipid nanoparticle (LNP)-based
- [Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage](https://resyca.com/resyca-soft-nasal-spray-adaptor-low-shear-forces-and-optimal-nasal-coverage/) - The Resyca® Nasal Soft Nasal Spray Adaptor is a single-use administration device for liquids to the nasal cavity, providing up to 50% coverage. The spray plume can be tailored to specific formulation requirements. Low shear forces make it gentle on nasal tissue. Read the fact sheet to learn more. Download
- [Resyca® PFSI™ Soft Mist Inhaler (SMI): Inhalation spray in a convenient device](https://resyca.com/resyca-pfsi-soft-mist-inhaler-smi-inhalation-spray-in-a-convenient-device/) - The Resyca® PFSI™ Soft Mist Inhaler uses pre-filled syringes for precise dose delivery and a gentle spray principle for fragile formulations. The pocket-sized device offers easy portability, with no batteries required. Download our fact sheet to discover the key benefits of the PFSI Soft Mist Inhaler. Download
- [Resyca® Pulmospray™ Soft Mist Inhaler (SMI): fast preparation and breath-synchronised delivery](https://resyca.com/resyca-pulmospray-soft-mist-inhaler-smi-fast-preparation-and-breath-synchronised-delivery/) - Using cutting-edge technology to generate a slow-moving aerosol cloud, Soft Mist Inhalers (SMIs) result in a high lung dose. The Resyca® Pulmospray™ soft mist nebuliser is a single-use device which is filled with the inhalation solution prior to administration – allowing for faster preparation in clinical trials. Download our fact sheet to discover the key benefits of the Pulmospray™
- [Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterisation, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis](https://resyca.com/pulmonary-delivery-of-favipiravir-inhalation-solution-for-covid-19-treatment-in-vitro-characterization-stability-in-vitro-cytotoxicity-and-antiviral-activity-using-real-time-cell-analysis/) - Authors: Ayca Yildiz Pekoz, Ozlem Akbal Dagistan, Hanan Fael, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Muge Serhatli, Gamze Cakirca, Saban Tekin, Leyla Semiha Sen, Mustafa Sevim, Lutfiye Mulazimoglu Durmusoglu and Berrak C. Yegen Journal: Drug Delivery, Volume 29(1), 2022 Abstract: Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients
- [Soft mist inhaler nebulisation by Rayleigh-breakup largely preserves functional integrity of liposomal mRNA in respirable aerosols](https://resyca.com/soft-mist-inhaler-nebulization-by-rayleigh-breakup-largely-preserves-functional-integrity-of-liposomal-mrna-in-respirable-aerosols/) - Authors: Achim Biesel, Sabine Maamari, Nils Salaw, Imco Sibum, Nicolas Buchmann, Brigitta Loretz, Elisabeth M. Zeisberg, Claus-Michael Lehr Journal: European Journal of Pharmaceutical Sciences, Volume 214, 2025 Abstract: Inhalable mRNA is an emerging field holding great potential for applications as mucosal vaccination, antiviral therapy or protein replacement therapies, but efficient delivery remains a bottleneck. In
- [SMIs & Soft Mist Nasal Sprays - A key defence in the fight against the next pandemic?](https://resyca.com/smis-soft-mist-nasal-sprays-a-key-defence-in-the-fight-against-the-next-pandemic/) - Authors: Wilbur de Kruif Publication: International Pharmaceutical Industry, Volume 14(2), 2022 Abstract: The COVID-19 outbreak has provided a number of lessons for the pharmaceutical industry to consider for future pandemics. Could soft mist inhalers (SMIs), and soft mist nasal sprays in particular, hold the key to improved vaccine delivery? Biologic vaccines are highly sensitive, and
- [Improved olfactory deposition of theophylline using a nanotech soft mist nozzle chip](https://resyca.com/improved-olfactory-deposition-of-theophylline-using-a-nanotech-soft-mist-nozzle-chip/) - Authors: Madeline X. Zhang, Frank Verhoeven, Pieter Ravensbergen, Stefan Kooij, Rick Geoffrion, Daniel Bonn, Cees J. M. van Rijn Journal: Pharmaceutics, Volume 16(2), 2024 Abstract: Currently, nasal administration of active pharmaceutical ingredients is most commonly performed using swirl-nozzle-based pump devices or pressurised syringes. However, they lead to limited deposition in the more active regions of
- [Transforming the biologics product lifecycle with inhalation innovation](https://resyca.com/transforming-the-biologics-product-lifecycle-with-inhalation-innovation/) - Authors: Nicolas Buchmann and Frank Verhoeven Publication: International Pharmaceutical Industry, Volume 16(1), 2024 Abstract: Biologics are reshaping modern healthcare, yet their full potential is often constrained by traditional administration routes. Recent advances in nasal inhalation, particularly soft mist nasal spray technologies, are redefining what is possible for sensitive biopharmaceutical formulations. The rapid growth of both
- [How soft mist inhalers support improved biopharma drug delivery](https://resyca.com/smi-technology-how-soft-mist-inhalers-support-improved-biopharma-drug-delivery/) - Authors: Nicolas Buchmann Publication: Drug Development & Delivery, Volume 24(7), 2024 Abstract: Worldwide, rising cases of chronic lung conditions, such as asthma, cystic fibrosis, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD), are driving demand for inhalation drug delivery devices. As respiratory diseases rise and biologics rapidly expand, the need for advanced, patient-friendly
- [Pulmonary delivery of favipiravir in rats reaches high local concentrations without causing oxidative lung injury or systemic side effects](https://resyca.com/pulmonary-delivery-of-favipiravir-in-rats-reaches-high-local-concentrations-without-causing-oxidative-lung-injury-or-systemic-side-effects/) - Authors: Ozlem Akbal-Dagistan , Mustafa Sevim, Leyla Semiha Sen, Nur Sena Basarir, Meltem Culha, Aybige Erturk, Hanan Fael, Engin Kaptan, Serap Sancar, Lutfiye Mulazimoglu Durmusoglu, Berrak C. Yegen and Ayca Yildiz-Pekoz Journal: Pharmaceutics, Volume 14(11), 2022 Abstract: Favipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration
- [Inhalation delivery of complex drugs – the next steps](https://resyca.com/inhalation-delivery-of-complex-drugs-the-next-steps-review-article-in-current-opinion-in-pharmacology-2017/) - Authors: Wilbur de Kruijf, Carsten Ehrhardt Journal: Current Opinion in Pharmacology, Volume 36, 2017 Abstract: This article, published in 2017 in Current Opinion in Pharmacology by Elsevier, gives a basic explanation about topical inhalation versus systemic delivery through inhalation. Several examples are given for products targeted to the central airways, the peripheral airways, for delivery
- [Degradation of lipid based drug delivery formulations during nebulisation](https://resyca.com/spraying-delicate-lnp-bio-formulations-scientific-article-published-in-medrxiv-2021/) - Authors: David M. Klein, Frank M. Verhoeven, Daniel Bonn, Sylvestre Bonnet, Cees J.M. van Rijn Journal: Chemical Physics, Volume 547, 2021 Abstract: Encapsulating pharmaceuticals in protective lipid based nanoparticles, and nebulising them towards the target area in the body offers a range of clinical advantages. However, the process of nebulization might possibly damage sensitive nanoparticle
- [Aerosol performance of the single-use Pulmospray soft mist inhaler for inhalation of high amounts of liquid formulations](https://resyca.com/aerosol-performance-of-the-single-use-pulmospray-soft-mist-inhaler-for-inhalation-of-high-amounts-of-liquid-formulations-scientific-poster-presented-at-isam-congress-2021/) - Authors: Bernhard Muellinger, Nicolas A Buchmann, Jody Bartholomew, Wilbur de Kruijf Event: ISAM Congress, 22 - 36th May 2021, Idaho, USA Abstract: Resyca have presented a poster on the performance of the Pulmospray® device at the ISAM conference 2021 in Boise Idaho. Unfortunately we could not be there in person but had to participate on-line.
- [Early effects of low molecular weight heparin therapy with soft mist inhaler for COVID-19-Induced Hypoxemia: A phase IIb trial](https://resyca.com/early-effects-of-low-molecular-weight-heparin-therapy-with-soft-mist-inhaler-for-covid-19-induced-hypoxemia-a-phase-iib-trial/) - Authors: Mustafa Erelel, Mert Kaskal, Ozlem Akbal-Dagistan, Halim Issever, Ahmet Serhan Dagistanli, Hilal Balkanci, Merve Sinem Oguz, Aygun Qarayeva, Meltem Culha, Aybige Erturk, Nur Sena Basarir, Gokben Sahin, Ali Yagiz Uresin, Ahmet Ogul Araman, Alpay Medetalibeyoglu, Tufan Tukek, Mustafa Oral Oncul, Ayca Yildiz-Pekoz Journal: Pharmaceutics, Volume 13 (11), 2021 Abstract: In COVID-19-induced acute respiratory distress
- [Do soft mist inhalers hold the key to faster inhalation drug development?](https://resyca.com/do-soft-mist-inhalers-hold-the-key-to-faster-inhalation-drug-development/) - Authors: Wilbur de Kruijf, Bernhard Müllinger Publication: OnDrug Delivery, No 131, April 11th 2022 Abstract: The rise of the biopharmaceutical segment has increased the value of the inhalation sector, with more and more drug developers exploring inhalation as an alternative delivery mechanism to the parenteral approach traditionally used for biologics. While inhalation is an ideal
- [Fluorescence-enabled evaluation of nasal tract deposition and coverage of pharmaceutical formulations in a silicone nasal cast using an innovative spray device](https://resyca.com/nasal-tract-deposition-in-nasal-cast-using-an-innovative-spray-device/) - Authors: Davide D’Angelo, Stefan Kooij, Frank Verhoeven, Fabio Sonvico, Cees van Rijn Journal: Journal of Advanced Research, Volume 44, 2023 Abstract: This publication covers the evaluation of nasal deposition and deposition patterns of an innovative nasal spray nozzles generating slow velocity soft mists. The methods involved studying the deposition pattern of a fluorescent liquid formulation
- [Low energy nebulisation preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery](https://resyca.com/low-energy-nebulization-preserves-integrity-of-sars-cov-2-mrna-vaccines-for-respiratory-delivery-scientific-article-in-nature-scientific-reports-2023/) - Authors: Cees J. M. van Rijn, Killian E. Vlaming, Reinout A. Bem, Rob J. Dekker, Albert Poortinga, Timo Breit, Selina van Leeuwen, Wim A. Ensink, Kelly van Wijnbergen, John L. van Hamme, Daniel Bonn & Teunis B. H. Geijtenbeek Journal: Nature Scientific Report, Volume 13(1), 2023 Abstract: Nebulisation of mRNA therapeutics can be used to
- [Advances in soft mist inhalers](https://resyca.com/advances-in-soft-mist-inhalers-review-article-in-expert-opinion-in-drug-delivery-2023/) - Authors: Varsha Komalla, Chun Yuen Jerry Wong, Imco Sibum, Bernhard Muellinger, Wietze Nijdam, Vishal Chaugule, Julio Soria, Hui Xin Ong, Nicolas A Buchmann, Daniela Traini Journal: Expert Opinion on Drug Delivery , Volume 20(8), 2023 Abstract: Soft mist inhalers (SMIs) are propellant-free inhalers that utilise mechanical power to deliver single or multiple doses of inhalable
- [Usability and inspiratory flow profiles of patients with pulmonary hypertension inhaling with a novel Soft Mist Inhaler (SMI)](https://resyca.com/usability-and-inspiratory-flow-profiles-of-patients-with-pulmonary-hypertension-inhaling-with-a-novel-soft-mist-inhaler-smi/) - Authors: B. Müllinger, N. Buchmann, R. Huedepohl, G. Prins Event: ISAM Congress, 26 - 30th August 2023, Saarbrücken, Germany Abstract: Good inhaler technique is key for an effective inhalation treatment and reduction of critical inhaler errors. Recent publications show that treatment effects can be improved if inhalers are easy to use and support patients with
- [Influence of fluid physiochemical properties on aerosolisation performance of a novel soft mist inhaler](https://resyca.com/influence-of-fluid-physiochemical-properties-on-aerosolization-performance-of-a-novel-soft-mist-inhaler/) - Authors: Varsha Komalla, Imco Sibum, Bernhard Muellinger, Wietze Nijdam, Vishal Chaugule, Julio Soria, Nicolas Buchmann, Hui Xin Ong, D. Traini Event: DDL 2023, 6 - 8 December 2023, Edinburgh, United Kingdom Abstract: Soft mist inhalers (SMIs) are propellant-free inhalers that are gaining interest in the delivery of drugs, especially proteins and biologics, due to the
- [Assessment of the delivery performance of a novel soft mist inhaler using a pre-filled syringe based container closure system](https://resyca.com/assessment-of-the-delivery-performance-of-a-novel-soft-mist-inhaler-using-a-pre-filled-syringe-based-container-closure-system/) - Authors: Pragathi Kamale Gurumurthy, Knut Sommerer, Imco Sibum, Nicolas Buchmann, Bernhard Müllinger Event: DDL 2023, 6 - 8 December 2023, Edinburgh, United Kingdom Abstract: Biological drugs are primarily delivered as water-based liquid formulations and require efficient delivery platforms when being delivered via the inhalation route. The soft mist inhaler tested within this study uses a
- [Assessing the variability of in silico lung deposition predictions when inhaling from soft mist inhalers with various air flow resistances](https://resyca.com/assessing-the-variability-of-in-silico-lung-deposition-predictions-when-inhaling-from-soft-mist-inhalers-with-various-air-flow-resistances/) - Authors: Nicolas A. Buchmann, Bernhard Muellinger Event: RDD 2024, 5-9th May 2024, Tucson, Arizona Abstract: When selecting a suitable inhaler for effective drug delivery, it is crucial to consider both particle/droplet size and inspiratory flow rate achievable with a specific device. Inspiratory flow rate varies significantly among inhalers due to different flow resistance. Novel SMIs,
- [A device screening method for predicting delivery of inhaled mRNA via a nebuliser](https://resyca.com/a-device-screening-method-for-predicting-delivery-of-inhaled-mrna-via-a-nebuliser/) - Authors: Imco Sibum, Bernhard Müllinger, Nicolas Buchmann Event: DDL 2023, 6 - 8 December 2023, Edinburgh, United Kingdom Abstract: A device screening method is presented which takes aerosol parameters, deposition modelling, and post aerosolisation mRNA integrity data to predict lung deposition of functional mRNA as a percentage of fill dose. In the prediction performed here,
- [Assessment of the novel soft mist Pre-filled Syringe Inhaler (PFSI) device performance after storage at sub 0 °C temperature conditions](https://resyca.com/assessment-of-the-novel-soft-mist-pre-filled-syringe-inhaler-pfsi-device-performance-after-storage-at-sub-0-c-temperature-conditions/) - Authors: Imco Sibum, Bernhard Müllinger, and Nicolas A. Buchmann Event: DDL 2024, 11 - 13 December 2024, Edinburgh, United Kingdom Abstract: Resyca’s PFSI device maintains anti-microbial ingress valve and delivery performance post-storage at freezing conditions. This finding further demonstrates the suitability of Resyca’s technology for the delivery of biological products such as proteins and RNA
- [Pre-filled syringe soft mist nasal spray for improved intranasal drug delivery](https://resyca.com/pre-filled-syringe-soft-mist-nasal-spray-for-improved-intranasal-drug-delivery/) - Authors: Frank Verhoeven, Pieter Ravensbergen, Imco Sibum, Bernhard Müllinger, Nicolas A. Buchmann Event: DDL 2024, 11 - 13 December 2024, Edinburgh, United Kingdom Abstract: The nasal administration route has garnered substantial interest for vaccination and nose-to-brain delivery via the olfactory region. Current swirl nozzle devices deliver less than 5-10% of their dose to the target
- [Targeted nasal delivery of LNP-mRNAs aerosolised by Rayleigh breakup technology](https://resyca.com/targeted-nasal-delivery-of-lnp-mrnas-aerosolised-by-rayleigh-breakup-technology/) - Authors: Hao-Ying Li, Abhimata Paramanandana, Sally Yunsun Kim, Luke Granger, Bahijja Tolulope Raimi-Abraham, Robin Shattock, Charalampos Makatsoris, Ben Forbes Journal: International Journal of Pharmaceutics, Volume 672, 2025 Abstract: The nasal delivery of mRNA vaccines attracts great interests in both academia and industry. While the lipid nanoparticle (LNP)-mRNA complexes are vulnerable and need a subtle process
- [Rayleigh-based soft mist inhalers preserve mRNA-LNP integrity for pulmonary delivery](https://resyca.com/rayleigh-based-soft-mist-inhalers-preserve-mrna-lnp-integrity-for-pulmonary-delivery/) - Authors: Patrick He, Imco Sibum, Wietze Nijdam, Nicolas Buchmann, Julio Soria, Hui Ong and Daniela Traini Journal: Journal of Drug Delivery Science and Technology, Volume 115, Part 1, 2026 Abstract: Pulmonary delivery of mRNA-lipid nanoparticles (mRNA-LNPs) offers a promising non-invasive route of administration for pulmonary gene therapy, vaccine applications, amongst others. However, aerosolisation can compromise
- [Enhancing drug delivery with innovative soft mist inhaler technology](https://resyca.com/enhancing-drug-delivery-with-innovative-soft-mist-inhaler-technology/) - Authors: Nicholas Buchmann, Bernhard Müllinger Publication: ONdrug Delivery 180, 26th November 2025 Abstract: With the increasing demand for new inhalation therapies, the need for efficient, patient-centric and sustainable delivery platforms is paramount. The Resyca PFSI is uniquely positioned to meet these needs, enabling precise and reliable delivery of even the most fragile molecules. Soft Mist
- [Resyca receives medical device regulation certificate from TÜV SÜD](https://resyca.com/press-release-resyca-receives-medical-device-regulation-certificate-from-tuv-sud/) - MDR certification strengthens Resyca’s leadership in soft mist drug-device combination products. Download Press Release Download MDR Certificate Enschede, Netherlands, January 28, 2025 – Resyca BV, a pioneering leader in the development and manufacturing of advanced inhalation drug delivery devices, proudly announces successful certification under the European Medical Device Regulation (MDR, Regulation (EU) 2017/745) by notified body
- [Cyrano Therapeutics and Resyca announce exclusive license agreement for soft mist nasal spray technology for the treatment of persistent smell loss](https://resyca.com/press-release-cyrano-therapeutics-and-resyca-announce-exclusive-license-agreement-for-soft-mist-nasal-spray-technology-for-the-treatment-of-persistent-smell-loss/) - Soft mist nasal spray technology designed to enhance drug deposition in the Olfactory region, increasing the potential for CYR-064’s therapeutic efficacy. Download Press Release Delray Beach, FL, and Enschede, Netherlands, March 18, 2025 – Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft
- [Resyca BV successfully recertified for ISO 13485 – valid until 2028](https://resyca.com/resyca-bv-successfully-recertified-for-iso-13485-valid-until-2028/) - We are pleased to announce that Resyca BV has successfully renewed its ISO 13485 certification, securing validity until 2028. This recertification underscores our commitment to maintaining the highest standards in quality management and regulatory compliance. Since obtaining our initial certification in 2022, we have continuously expanded and strengthened our quality framework, achieving additional certifications, including
- [Silo Pharma and Resyca BV partner on device and CMC development for intranasal PTSD drug SPC-15](https://resyca.com/press-release-silo-pharma-and-resyca-bv-partner-on-device-and-cmc-development-for-intranasal-ptsd-drug-spc-15/) - Nose-to-brain drug Delivery shows promising patient safety and therapeutic benefitthe device and CMC development master plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional
- [Spray nozzle unit high volume manufacturing at Medspray](https://resyca.com/spray-nozzle-unit-high-volume-manufacturing-at-medspray/) - Spray nozzle unit manufacturing at Medspray in The Netherlands. At Medspray in Enschede, The Netherlands, the manufacturing of our soft mist spray nozzle units takes place under clean room conditions on an automated production line, upscaled for high volumes. Several robotic machines assemble the silicon nozzle plates into their plastic holders. The nozzle plates are
- [Successful phase 2/3 study with Heparin delivered with Pulmospray](https://resyca.com/successful-phase-2-3-study-with-heparin-delivered-with-pulmospray/) - Istanbul University has used Pulmospray to deliver inhaled Heparin to COVID patients with promising results. The University of Istanbul with investigators Prof. Mustafa Erelel and Prof. Ayca Yildiz Pekoz recently completed a clinical study on COVID-19 with the Pulmospray® inhaler from Resyca. The endpoints of the study were improvement in clinical status (e.g. hypoxemia) and
- [Bespak – device manufacturing](https://resyca.com/bespak-device-manufacturing/) - Bespak is Resycas device manufacturing partner for high volume manufacturing of soft mist inhaler devices. Resyca is a joint venture between Bespak and Medspray. Bespak has a strong franchise and is an established supplier of inhalation devices to the pharma industry. By having access to this proprietary device manufacturing line, Resyca can provide shorter time
- [First pharmaceutical customer on the soft mist inhaler (SMI) platform](https://resyca.com/first-pharmaceutical-customer-on-the-soft-mist-inhaler-smi-platform-2/) - Resyca has boarded its first pharmaceutical customer on the soft mist inhaler (SMI) platform. An agreement has been signed involving milestones and royalties for exclusivity on the specific drug product. The innovative SMI platform consists of a portable disposable nebuliser featuring a microspray nozzle developed by spray specialist Medspray, which is designed to generate a
- [Stevanato Group collaborates with Resyca ® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products](https://resyca.com/press-release-stevanato-group-collaborates-with-resyca-to-develop-and-manufacture-pre-fillable-syringes-for-use-in-a-new-soft-mist-inhaler-for-the-inhalation-of-sensitive-biological-p-2/) - The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Resyca®’s proprietary soft mist inhalers. Stevanato Group S.p.A. (NYSE: STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Resyca® BV (a joint venture
- [Pharmaceutical scientist Imco Sibum about our soft mist inhaler](https://resyca.com/pharmaceutical-scientist-imco-sibum-about-our-soft-mist-inhaler-2/) - The multifold benefits of our Soft Mist Inhaler Could you tell us more about the soft mist inhaler? Resyca’s soft mist inhalers are devices which take a dissolved drug (the formulation) and aerosolize it in small droplets suitable for inhalation. This aerosolization happens by use of a nozzle plate containing small holes. These holes, or
- [Joint venture Recipharm and Medspray](https://resyca.com/press-release-joint-venture-recipharm-and-medspray/) - Recipharm’s investment in Resyca has been made through its subsidiary Recipharm BV. This investment enables exciting opportunities for pharmaceuticals being delivered by soft mist inhalers. Resyca will operate development facilities in Enschede, The Netherlands and Munich, Germany. Spray nozzles will be supplied exclusively from Medspray in the Netherlands. It is envisaged that commercial supply of
- [The potential of nasal sprays for vaccination](https://resyca.com/the-potential-of-nasal-sprays-for-vaccination-2/) - Do vaccines delivered via a soft mist nasal spray device hold the key to an enhanced immunization response? While the COVID-19 pandemic was marked by the number of successes achieved by the pharmaceutical industry, it’s clear that there are still lessons to be learnt about improving our response to the next viral threat. One vitally
- [Successful clinical trial in COVID with Heparin in Pulmospray](https://resyca.com/successful-clinical-trial-in-covid-with-heparin-in-pulmospray/) - Clinical trial success in COVID19 with heparin in Pulmospray®. Istanbul University, Professor Dr. Mustafa Erelel and Professor Dr. Ayca Yildiz-Pekoz, recently completed their investigator-supported clinical study with low molecular weight heparin with our Pulmospray device. Resyca donated these devices to this COVID-related research program at the start of the pandemic. Investigators reported promising results of
- [Thaerapy BV and Resyca BV announce exclusive licence agreement for Soft Mist Inhaler technology](https://resyca.com/press-release-thaerapy-bv-and-resyca-bv-announce-exclusive-license-agreement-for-soft-mist-inhaler-technology/) - Thaerapy BV, a pharmaceutical drug product development company, and Resyca® BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, announced today the signing of an exclusive license agreement for Resyca®’s soft mist inhaler for the development of a treatment for pulmonary arterial hypertension (PAH).
- [Aero Pump and Resyca partner to launch Ultra Soft Nasal Pump Spray, targeting precise nasal drug delivery applications](https://resyca.com/press-release-aero-pump-and-resyca-partner-to-launch-ultra-soft-nasal-pump-spray-targeting-precise-nasal-drug-delivery-applications/) - Now available for licensing, Ultra Soft Nasal Pump Spray leverages innovative spray nozzle chip technology for superior nasal cavity coverage – ideal for nose-to-brain therapies, vaccination, and other advanced multidose nasal applications. Enschede, Netherlands, October 3, 2024 – Aero Pump and Resyca are proud to announce their collaboration in the launch of the innovative Ultra
- [Resyca shareholder Bespak announces successful completion of spin-out from Recipharm Group](https://resyca.com/press-release-resyca-shareholder-bespak-announces-successful-completion-of-spin-out-from-recipharm-group/) - Separation creates leading global CDMO focused on inhaled and nasal drug delivery Enschede, Netherlands and Holmes Chapel, UK; Tuesday 2nd April 2024 — Bespak, backed by EQT Private Equity, today announced the finalisation of its separation from the Recipharm Group to form a new standalone entity. Formerly the Advanced Delivery Systems Business Unit of Recipharm,
- [Recipharm, Medspray and Resyca enter into exclusive licence agreement to develop nasally-delivered drug products using proprietary soft mist technology](https://resyca.com/press-release-recipharm-medspray-and-resyca-enter-into-exclusive-license-agreement-to-develop-nasally-delivered-drug-products-using-proprietary-soft-mist-technology/) - Partnership will help bring breakthroughs in the nasal delivery of fragile biologics and small molecules to market Recipharm, a leading contract development and manufacturing organisation (CDMO) is pleased to announce an exclusive licence and collaboration agreement with Medspray and Resyca, to develop soft mist nasal delivery devices for single and combination drug products. This collaboration
- [Resyca announces leadership changes](https://resyca.com/press-release-resyca-announces-leadership-changes/) - Resyca®, a leading provider of inhaler technology, announced today that Nicolas Buchmann, currently Resyca’s Head of Development and Project Management, will assume the role of Chief Technical Officer. Nicolas brings extensive experience in the pharmaceutical industry and has played a pivotal role in the development of Resyca®’s PFSITM and PulmosprayTM platforms. Nicolas Buchmann replaces Wilbur
- [Resyca brand and website](https://resyca.com/resyca-brand-and-website/) - The new Resyca website has been launched. Since founding Resyca in December 2020 and getting Recipharm on board in February Since the founding of Resyca in December 2020 and the inclusion of Recipharm in February 2021, Resyca and Brand Specials have worked together on the definition of the Resyca brand values, a suitable corporate house

## Pages

- [Home](https://resyca.com/) - At Resyca we make syringe and cartridge based soft mist inhaler devices and nasal sprays for liquid formulations.
- [Our Leadership](https://resyca.com/our-leadership/) - Our Leadership At Resyca BV, our leadership team brings together deep expertise in the development, commercialisation, and lifecycle management of inhalation and nasal drug-device combination products. With decades of combined experience in the pharmaceutical and device industries, our leaders guide Resyca’s mission to deliver innovative, patient-centric solutions that meet the highest standards of quality and
- [Partnering](https://resyca.com/partnering/) - Partnering Partner with Resyca to leverage our expertise, advanced platforms, and end-to-end services. Together, we can accelerate your product from concept to market and transform the future of drug delivery. From Concept to Commercialisation Seamless Innovation in Drug-Device Delivery At Resyca, we help to bring advanced drug-device combination products to market faster and more efficiently.
- [Soft Nasal Spray Adaptor](https://resyca.com/soft-nasal-spray-adaptor/) - Soft Nasal Spray Adaptor The Soft Nasal Spray Adaptor brings gentle, high-precision soft mist delivery directly to the nasal cavity. Designed for single-use convenience, it ensures optimal coverage of the nasal passages and olfactory region, opening new possibilities for nose-to-brain therapies and nasal biologics. Device Overview Single-Use Soft Nasal Spray, Maximum Impact The Soft Nasal
- [Pulmospray](https://resyca.com/pulmospray/) - Pulmospray Pulmospray™ with Respi Lever Drive™A disposable soft mist nebuliser delivering precision therapy with simplicity and ease. A disposable soft mist nebuliser delivering precision therapy with simplicity and ease.","link":"wp-content\/uploads\/2025\/12\/Resyca\u00ae-Pulmospray\u2122-Soft-Mist-Inhaler.pdf","position":"relative","position_z_index":"1","text_align":"center","text_align_fallback":"center","title_element":"div","title_style":"h4"}}]}]}]},{"type":"section","props":{"image_position":"center-center","preserve_color":true,"style":"secondary","title_breakpoint":"xl","title_position":"top-left","title_rotation":"left","vertical_align":"middle","width":"default"},"children":[{"type":"row","children":[{"type":"column","props":{"image_position":"center-center","position_sticky_breakpoint":"m"},"children":[{"type":"panel","props":{"content":"The Pulmospray\u2122 with Respi Lever Drive\u2122 is a single use, disposable soft mist nebuliser designed for simplicity, reliability, and precision in clinical settings.\nIts 1 mL plastic syringe
- [PFSI](https://resyca.com/pfsi/) - Pre-Filled Syringe Soft Mist Inhaler (PFSI™) is a ready-to-use, patient-friendly platform combining high-performance drug delivery with everyday convenience.
- [Publications](https://resyca.com/publications/) - Publications Your Breakthrough. Our Capabilities. Ready When You Are. Resyca is here to support your journey. Let’s shape the future of soft mist inhalation together. Contact Us
- [Technology](https://resyca.com/technology/) - Technology Our advanced technology supports high-efficiency inhaled and nasal drug delivery, helping to reduce waste, enhance cost-effectiveness, and simplify drug delivery for patients. Spray Nozzle Technology Gentle, Precise Sprays Designed for Every Patient At the heart of Resyca’s soft mist technology is a 1 × 1 mm silicon micro-pore nozzle chip, fabricated using advanced semiconductor
- [About Us](https://resyca.com/about-resyca/) - Resyca BV is redefining drug delivery through innovative soft mist inhalation technology. We specialise in developing drug-device combination products
- [Ultra Soft Nasal Pump Spray](https://resyca.com/ultra-soft-nasal-pump-spray/) - Ultra Soft Nasal Pump Spray The Ultra Soft Nasal Pump Spray delivers a fine, low-velocity mist with unmatched control. Designed for accurate deposition and reliable performance, it sets a new standard for advanced nasal drug delivery such as CNS therapies, nasal vaccines, or sensitive biologics. Device Overview Precision, Comfort, and Safety in Every Spray The
- [Contact Us](https://resyca.com/contact-us/) - Contact Us From concept to clinic, Resyca’s capabilities are built to support your breakthrough in inhalation therapy. We’re ready when you are. Contact our team to start the conversation. Where We Work Resyca operates from two key locations. Munich, GermanyOur commercial and strategic hub, close to leading pharmaceutical partners and regulatory bodies. Enschede, NetherlandsOur technology
- [Quality & Regulatory](https://resyca.com/quality-regulatory/) - Quality & Regulatory Resyca is committed to complying with applicable legal and regulatory requirements, standards, and internationally recognised best practices. We aim to meet the high expectations of our pharmaceutical partners regarding the quality, safety, and efficacy of our nasal delivery and inhalation devices, as well as all related services. Certified Quality Systems ISO 13485Resyca
- [Events](https://resyca.com/events/) - Events CPHI India 25–27 Nov 2025 India Expo Centre, Greater Noida, Delhi NCR, India Attending Learn More Drug Delivery to the Lung (DDL) 10–12 Dec 2025 Edinburgh International Conference Centre, UK Poster Presentations Learn More Your Breakthrough. Our Capabilities. Ready When You Are. Resyca is here to support your journey. Let’s shape the future of
- [Drug Delivery to the Lung (DDL)](https://resyca.com/drug-delivery-to-the-lung-ddl/) - Drug Delivery to the Lung (DDL) 10–12 Dec 2025 WHERE: Edinburgh International Conference Centre, UK. TYPE: Poster Presentations Join us at the Drug Delivery to the Lung (DDL) Conference where innovation meets inhalation. At Resyca, we bring your inhalation breakthroughs to life. Our propellant-free soft mist technology blends precision engineering, sustainability and patient-centric design, making
- [CPHI India](https://resyca.com/cphi-india/) - CPHI India 25–27 Nov 2025 WHERE: India Expo Centre, Greater Noida, Delhi NCR, India. TYPE: Attending Meet Resyca at CPHI India and discover how our customisable soft mist inhalation platforms and complete end-to end services can make your journey to market seamless. At Resyca, we specialise in propellant-free soft mist inhalation and nasal spray devices
- [BIO-Europe](https://resyca.com/bio-europe/) - Bio-Europe 3–5 Nov 2025 WHERE: Vienna Congress and Convention Center, Vienna, Austria. TYPE: Attending At Resyca, we’re redefining how pulmonary and nasal therapies reach patients. Our next-generation soft mist inhalation technology delivers exceptional efficiency, low residual volumes and proven scalability — all while ensuring patient comfort and sustainable design. From early-stage biologics to established formulations,
- [Rescon USA Summit 2025](https://resyca.com/rescon-usa-summit-2025/) - Rescon USA Summit 2025 5–6 Nov 2025 WHERE: San Francisco, USA. TYPE: Speaker Presentation Meet Resyca at RESCON USA Summit 2025 to elevate your pulmonary and nasal drug delivery strategy. In the evolving world of inhalation and respiratory drug delivery, efficient, scalable and patient-centric platforms are more critical than ever. At Resyca, we partner with
- [Web Terms](https://resyca.com/web-terms/) - Terms & Conditions (1) Introduction These terms and conditions govern your use of our website; by using our website, you accept these terms and conditions in full. If you disagree with any part of these terms and conditions, do not use our website. (2) Intellectual property rights Unless otherwise stated, we or our licensors own
- [Privacy Policy](https://resyca.com/privacy-policy/) - Privacy Statement Privacy Statement Resyca B.V. and its affiliated companies (Resyca GmbH), (hereafter: “Resyca”) respect the privacy of all users of their website and ensure that the personal information you provide to us is handled confidentially. Scope This Privacy Statement applies to all personal data of visitors, customers and other third parties whom Resyca has
- [Prefilled Syringe Nasal Spray](https://resyca.com/prefilled-syringe-nasal-spray/)
- [PRFY](https://resyca.com/prfy/)
- [Terms & Conditions](https://resyca.com/terms-conditions/)
- [Careers](https://resyca.com/careers-2/)
- [Nasal](https://resyca.com/nasal/)
- [Pulmonary](https://resyca.com/pulmonary/)
- [Platforms](https://resyca.com/platforms/)

## Categories

- [Uncategorized](https://resyca.com/category/uncategorized/)
- [Cases](https://resyca.com/category/cases/)
- [News](https://resyca.com/category/news/)
- [Publications](https://resyca.com/category/publications/)
- [Journal](https://resyca.com/category/journal/)
- [Poster](https://resyca.com/category/poster/)
- [Article](https://resyca.com/category/article/)
- [Factsheets](https://resyca.com/category/factsheets/)

## Tags

- [Technology](https://resyca.com/tag/technology/)
- [Inhalation platform](https://resyca.com/tag/inhalation-platform/)
- [Nasal platform](https://resyca.com/tag/nasal-platform/)
- [Clinical](https://resyca.com/tag/clinical/)
- [Partnering](https://resyca.com/tag/partnering/)
- [PFSI](https://resyca.com/tag/pfsi/)